Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 133,196,768
  • Shares Outstanding, K 588,247
  • Annual Sales, $ 23,362 M
  • Annual Income, $ 7,842 M
  • 60-Month Beta 0.97
  • Price/Sales 5.66
  • Price/Cash Flow 11.89
  • Price/Book 14.04
  • Price/Earnings ttm 14.56
  • Earnings Per Share ttm 15.44
  • Most Recent Earnings 4.17 on 04/30/20
  • Next Earnings Date N/A
  • Annual Dividend & Yield 6.40 (2.83%)
  • Most Recent Dividend 1.600 on 05/15/20
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 3.71
  • Number of Estimates 12
  • High Estimate 4.21
  • Low Estimate 2.74
  • Prior Year 3.97
  • Growth Rate Est. (year over year) -6.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
223.61 +0.98%
on 05/22/20
244.95 -7.81%
on 04/28/20
-10.47 (-4.43%)
since 04/24/20
3-Month
177.05 +27.54%
on 03/23/20
244.95 -7.81%
on 04/28/20
+11.27 (+5.25%)
since 02/26/20
52-Week
166.68 +35.48%
on 05/31/19
244.99 -7.83%
on 12/17/19
+54.53 (+31.84%)
since 05/24/19

Most Recent Stories

More News
Coronavirus Vaccine Development Gathers Steam: 4 Winners

Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

SNY : 47.78 (+1.01%)
GILD : 73.02 (-0.44%)
MRNA : 64.45 (-6.59%)
GSK : 40.85 (-0.10%)
AMGN : 224.78 (-0.73%)
NVAX : 53.38 (+15.77%)
ADPT : 40.94 (-1.89%)
Skin Cancer Treatment Market to Reach $14.55 Billion by 2027; Increasing Regulatory Approvals Will Provide Impetus to Market Growth, says Fortune Business Insights(TM)

The global skin cancer treatment market size is projected to reach USD 14.55 billion by the end of 2027. The increasing prevalence of non-melanoma cancer across the world will have a huge impact on market...

AMGN : 224.78 (-0.73%)
BMY : 60.64 (-0.25%)
GSK : 40.85 (-0.10%)
NVS : 85.06 (+0.18%)
PFE : 37.58 (+0.21%)
REGN : 540.69 (-5.13%)
Roche Acquires Stratos Genomics, Presents Data on NMOSD Drug

Roche (RHHBY) acquires Stratos Genomics to advance the development of its nanopore sequencer as well as releases positive data on its NMOSD Drug.

RHHBY : 44.5300 (-0.38%)
MRK : 77.26 (+1.17%)
AMGN : 224.78 (-0.73%)
AGN : 193.02 (+0.02%)
Simple Secrets Anyone Can Use to Reach Early Retirement - May 21, 2020

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices,...

AMGN : 224.78 (-0.73%)
BMY : 60.64 (-0.25%)
ABBV : 92.87 (+0.84%)
Amgen Announces Voting Results Of Annual Meeting Of Stockholders

, /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders on , held virtually this year due to the COVID-19 pandemic. More than 88 percent...

AMGN : 224.78 (-0.73%)
Global Biosimilar Monoclonal Antibodies (mAbs) Market Report 2020, Featuring Amgen, Biocon, BioXpress Therapeutics, Celltrion and Novartis AG

, /PRNewswire/ -- The report has been added to offering.

AMGN : 224.78 (-0.73%)
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

REGN : 540.69 (-5.13%)
SNY : 47.78 (+1.01%)
PFE : 37.58 (+0.21%)
GILD : 73.02 (-0.44%)
MRNA : 64.45 (-6.59%)
GSK : 40.85 (-0.10%)
AMGN : 224.78 (-0.73%)
CYDY : 3.2200 (+3.87%)
ADPT : 40.94 (-1.89%)
BNTX : 50.60 (-0.84%)
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMGN : 224.78 (-0.73%)
The Extreme Risks of Trading Your Own Retirement Assets - May 18, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

ABBV : 92.87 (+0.84%)
AMGN : 224.78 (-0.73%)
APTS : 7.72 (+6.19%)
Coronavirus (COVID-19) Business Impact - New Research on Women Health Industry: Future of investment opportunities, market share & trends to 2027

MENAFN14052020007010847ID1100162919

ABT : 91.22 (-0.27%)
AGN : 193.02 (+0.02%)
AMGN : 224.78 (-0.73%)
BAYRY : 16.8500 (+6.92%)
LLY : 148.44 (-1.80%)
GSK : 40.85 (-0.10%)
NBIX : 125.50 (+0.56%)
NVS : 85.06 (+0.18%)
NOVN : 0.4134 (+3.35%)
NVO : 64.27 (-0.86%)
PFE : 37.58 (+0.21%)
RDUS : 13.22 (+3.93%)
TXMD : 1.2800 (+2.40%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 228.76
1st Resistance Point 227.60
Last Price 224.78
1st Support Level 224.44
2nd Support Level 222.44

See More

52-Week High 244.99
Last Price 224.78
Fibonacci 61.8% 215.08
Fibonacci 50% 205.83
Fibonacci 38.2% 196.59
52-Week Low 166.68

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar